U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C25H35N3O6S
Molecular Weight 505.627
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of AMPRENAVIR

SMILES

CC(C)CN(C[C@@H](O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]2CCOC2)S(=O)(=O)C3=CC=C(N)C=C3

InChI

InChIKey=YMARZQAQMVYCKC-OEMFJLHTSA-N
InChI=1S/C25H35N3O6S/c1-18(2)15-28(35(31,32)22-10-8-20(26)9-11-22)16-24(29)23(14-19-6-4-3-5-7-19)27-25(30)34-21-12-13-33-17-21/h3-11,18,21,23-24,29H,12-17,26H2,1-2H3,(H,27,30)/t21-,23-,24+/m0/s1

HIDE SMILES / InChI
Molecular Formula C25H35N3O6S
Molecular Weight 505.627
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/23519392 | https://www.ncbi.nlm.nih.gov/pubmed/11152018 | https://www.ncbi.nlm.nih.gov/pubmed/15341507

Amprenavir is an inhibitor of HIV-1 protease. Amprenavir binds to the active site of HIV-1 protease and thereby prevents the processing of viral gag and gag-pol polyprotein precursors, resulting in the formation of immature non-infectious viral particles. Amprenavir-containing combination regimens have shown virological efficacy, and have generally been well tolerated, in patients with HIV infection (primarily treatment-naive or protease inhibitor-naive). Fosamprenavir (GW433908, Lexiva, Telzir) is an oral prodrug of amprenavir, with a reduced daily pill burden. The use of protease inhibitors has also been associated with dyslipidemia and an increased risk of cardiovascular disease. Amprenavir activates Pregnane X receptor to mediate dyslipidemia.

CNS Activity

Originator

Approval Year

1999
174
Targets

Targets

Primary TargetPharmacologyConditionPotency
Agonist
2678
 8.6 µM [EC50]
Inhibitor
8297
 2.5 µM [IC50]
Inhibitor
8297
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
AGENERASE

Approved Use

AGENERASE (amprenavir) is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.

Launch Date

1999
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
5.36 μg/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/21007lbl.pdf
1200 mg 2 times / day multiple, oral
dose: 1200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
AMPRENAVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
6.18 μg/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/21007lbl.pdf
1200 mg single, oral
dose: 1200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AMPRENAVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: HIGH-FAT
9.72 μg/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/21007lbl.pdf
1200 mg single, oral
dose: 1200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AMPRENAVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
6.77 μg/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/21007lbl.pdf
20 mg/kg bw 2 times / day multiple, oral
dose: 20 mg/kg bw
route of administration: Oral
experiment type: MULTIPLE
co-administered:
AMPRENAVIR plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: UNKNOWN
food status: UNKNOWN
3.99 μg/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/21007lbl.pdf
15 mg/kg bw 3 times / day multiple, oral
dose: 15 mg/kg bw
route of administration: Oral
experiment type: MULTIPLE
co-administered:
AMPRENAVIR plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
18.5 μg × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/21007lbl.pdf
1200 mg 2 times / day multiple, oral
dose: 1200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
AMPRENAVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
22.06 μg × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/21007lbl.pdf
1200 mg single, oral
dose: 1200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AMPRENAVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: HIGH-FAT
28.05 μg × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/21007lbl.pdf
1200 mg single, oral
dose: 1200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AMPRENAVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
15.46 μg × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/21007lbl.pdf
20 mg/kg bw 2 times / day multiple, oral
dose: 20 mg/kg bw
route of administration: Oral
experiment type: MULTIPLE
co-administered:
AMPRENAVIR plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: UNKNOWN
food status: UNKNOWN
8.73 μg × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/21007lbl.pdf
15 mg/kg bw 3 times / day multiple, oral
dose: 15 mg/kg bw
route of administration: Oral
experiment type: MULTIPLE
co-administered:
AMPRENAVIR plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
8.85 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/21007lbl.pdf
1200 mg 2 times / day multiple, oral
dose: 1200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
AMPRENAVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
10%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/21007lbl.pdf
1200 mg 2 times / day multiple, oral
dose: 1200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
AMPRENAVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
1200 mg 2 times / day multiple, oral
Recommended
Dose: 1200 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 2 times / day
Co-administed with::
lamivudine, po(150 mg, BID)
zidovudine, po(300 mg, BID)
Sources:
https://pubmed.ncbi.nlm.nih.gov/11192131
Page: p.1387
unhealthy, 21-62
n = 113
Health Status: unhealthy
Condition: HIV-1 infection
Age Group: 21-62
Sex: M+F
Population Size: 113
Sources:
https://pubmed.ncbi.nlm.nih.gov/11192131
Page: p.1387
Disc. AE: Nausea, Vomiting...
AEs leading to
discontinuation/dose reduction:
Nausea (12%)
Vomiting (6%)
Loose stools (3%)
Abdominal pain (2%)
Abdominal discomfort (2%)
Rash (3%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/11192131
Page: p.1387
1200 mg single, oral
Recommended
Dose: 1200 mg
Route: oral
Route: single
Dose: 1200 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/10390223
Page: p.1688
unhealthy, 33+/-6.7
n = 12
Health Status: unhealthy
Condition: HIV-1 infection
Age Group: 33+/-6.7
Sex: M+F
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/10390223
Page: p.1688
Sources:
https://pubmed.ncbi.nlm.nih.gov/10390223
Page: p.1688
1200 mg 2 times / day multiple, oral
Recommended
Dose: 1200 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021007s017lbl.pdf
Page: p.11
unhealthy
Health Status: unhealthy
Condition: HIV-1 infection
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021007s017lbl.pdf
Page: p.11
Disc. AE: Reaction skin, Stevens-Johnson syndrome...
AEs leading to
discontinuation/dose reduction:
Reaction skin (grade 3-4)
Stevens-Johnson syndrome (grade 3-4)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021007s017lbl.pdf
Page: p.11
AEs

AEs

AESignificanceDosePopulation
Nausea 12%
Disc. AE
1200 mg 2 times / day multiple, oral
Recommended
Dose: 1200 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 2 times / day
Co-administed with::
lamivudine, po(150 mg, BID)
zidovudine, po(300 mg, BID)
Sources:
https://pubmed.ncbi.nlm.nih.gov/11192131
Page: p.1387
unhealthy, 21-62
n = 113
Health Status: unhealthy
Condition: HIV-1 infection
Age Group: 21-62
Sex: M+F
Population Size: 113
Sources:
https://pubmed.ncbi.nlm.nih.gov/11192131
Page: p.1387
Abdominal discomfort 2%
Disc. AE
1200 mg 2 times / day multiple, oral
Recommended
Dose: 1200 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 2 times / day
Co-administed with::
lamivudine, po(150 mg, BID)
zidovudine, po(300 mg, BID)
Sources:
https://pubmed.ncbi.nlm.nih.gov/11192131
Page: p.1387
unhealthy, 21-62
n = 113
Health Status: unhealthy
Condition: HIV-1 infection
Age Group: 21-62
Sex: M+F
Population Size: 113
Sources:
https://pubmed.ncbi.nlm.nih.gov/11192131
Page: p.1387
Abdominal pain 2%
Disc. AE
1200 mg 2 times / day multiple, oral
Recommended
Dose: 1200 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 2 times / day
Co-administed with::
lamivudine, po(150 mg, BID)
zidovudine, po(300 mg, BID)
Sources:
https://pubmed.ncbi.nlm.nih.gov/11192131
Page: p.1387
unhealthy, 21-62
n = 113
Health Status: unhealthy
Condition: HIV-1 infection
Age Group: 21-62
Sex: M+F
Population Size: 113
Sources:
https://pubmed.ncbi.nlm.nih.gov/11192131
Page: p.1387
Loose stools 3%
Disc. AE
1200 mg 2 times / day multiple, oral
Recommended
Dose: 1200 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 2 times / day
Co-administed with::
lamivudine, po(150 mg, BID)
zidovudine, po(300 mg, BID)
Sources:
https://pubmed.ncbi.nlm.nih.gov/11192131
Page: p.1387
unhealthy, 21-62
n = 113
Health Status: unhealthy
Condition: HIV-1 infection
Age Group: 21-62
Sex: M+F
Population Size: 113
Sources:
https://pubmed.ncbi.nlm.nih.gov/11192131
Page: p.1387
Rash 3%
Disc. AE
1200 mg 2 times / day multiple, oral
Recommended
Dose: 1200 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 2 times / day
Co-administed with::
lamivudine, po(150 mg, BID)
zidovudine, po(300 mg, BID)
Sources:
https://pubmed.ncbi.nlm.nih.gov/11192131
Page: p.1387
unhealthy, 21-62
n = 113
Health Status: unhealthy
Condition: HIV-1 infection
Age Group: 21-62
Sex: M+F
Population Size: 113
Sources:
https://pubmed.ncbi.nlm.nih.gov/11192131
Page: p.1387
Vomiting 6%
Disc. AE
1200 mg 2 times / day multiple, oral
Recommended
Dose: 1200 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 2 times / day
Co-administed with::
lamivudine, po(150 mg, BID)
zidovudine, po(300 mg, BID)
Sources:
https://pubmed.ncbi.nlm.nih.gov/11192131
Page: p.1387
unhealthy, 21-62
n = 113
Health Status: unhealthy
Condition: HIV-1 infection
Age Group: 21-62
Sex: M+F
Population Size: 113
Sources:
https://pubmed.ncbi.nlm.nih.gov/11192131
Page: p.1387
Reaction skin grade 3-4
Disc. AE
1200 mg 2 times / day multiple, oral
Recommended
Dose: 1200 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021007s017lbl.pdf
Page: p.11
unhealthy
Health Status: unhealthy
Condition: HIV-1 infection
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021007s017lbl.pdf
Page: p.11
Stevens-Johnson syndrome grade 3-4
Disc. AE
1200 mg 2 times / day multiple, oral
Recommended
Dose: 1200 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 2 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021007s017lbl.pdf
Page: p.11
unhealthy
Health Status: unhealthy
Condition: HIV-1 infection
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021007s017lbl.pdf
Page: p.11
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:40050
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:40050
ChemicalBook
CB4186139
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB4186139
MolPort
MolPort-000-883-856
https://www.molport.com/shop/molecule-link/MolPort-000-883-856
Selleck Chemicals
Amprenavir-(Agenerase)
http://www.selleckchem.com/products/Amprenavir-(Agenerase).html
ZINC
ZINC000003809192
http://zinc15.docking.org/substances/ZINC000003809192
eMolecules
877446
https://www.emolecules.com/cgi-bin/more?vid=877446
PubMed

PubMed

TitleDatePubMed
Metabolic disposition and pharmacokinetics of [14C]-amprenavir, a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, administered as a single oral dose to healthy male subjects.
2001 Apr
Open-label phase II trial of amprenavir, abacavir, and fixed-dose zidovudine/lamivudine in newly and chronically HIV-1--infected patients.
2001 Apr 1
HIV and drug allergy.
2001 Aug
Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience.
2001 Dec
Therapeutic drug monitoring of HIV protease inhibitors using high-performance liquid chromatography with ultraviolet or photodiode array detection.
2001 Dec
Human immunodeficiency virus type 1 hypersusceptibility to amprenavir in vitro can be associated with virus load response to treatment in vivo.
2001 Dec 15
Safety profile and tolerability of amprenavir in patients enrolled in an early access program.
2001 Feb
Structure-based design of non-peptide HIV protease inhibitors.
2001 Jan-Feb
Phase III trials for new PI.
2001 Mar
Sequencing of protease inhibitor therapy: insights from an analysis of HIV phenotypic resistance in patients failing protease inhibitors.
2001 Mar 30
[Simultaneous quantitative determination of amprenavir and indinavir in human plasma by high-performance liquid chromatography].
2001 Mar-Apr
[Drug interactions with antiretroviral agents].
2001 May-Jun
New developments in anti-HIV chemotherapy.
2001 Nov
Anti-human immunodeficiency virus drugs are ineffective against Pneumocystis carinii in vitro and in vivo.
2001 Nov 15
Effectors of HIV-1 protease peptidolytic activity.
2001 Sep 18
Simultaneous determination of the six HIV protease inhibitors (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir) plus M8 nelfinavir metabolite and the nonnucleoside reverse transcription inhibitor efavirenz in human plasma by solid-phase extraction and column liquid chromatography.
2002 Apr
Central nervous system toxicity and amprenavir oral solution.
2002 Jan
[Advances in the domain of HIV].
2002 Jan 19
Longitudinal use of phenotypic resistance testing to HIV-1 protease inhibitors in patients developing HAART failure.
2002 Jul
In vitro antiviral interaction of lopinavir with other protease inhibitors.
2002 Jul
The pharmacokinetics of amprenavir, zidovudine, and lamivudine in the genital tracts of men infected with human immunodeficiency virus type 1 (AIDS clinical trials group study 850).
2002 Jul 15
Fosamprenavir. Vertex Pharmaceuticals/GlaxoSmithKline.
2002 Mar
Lipodystrophy update.
2002 Mar
Drug interactions between HIV protease inhibitors based on physiologically-based pharmacokinetic model.
2002 Mar
The utility of inhibitory quotients in determining the relative potency of protease inhibitors.
2002 Mar 29
Delavirdine increases drug exposure of ritonavir-boosted protease inhibitors.
2002 Mar 29
FDA approves new dosing for amprenavir and ritonavir combination.
2002 Mar 8
Prevalence of the HIV protease mutation N88S causing hypersensitivity to amprenavir.
2002 May 1
Patents

Patents

JP2009526755A
447
JP2011508764A
18
JP2011510954A
143
JP4676536B2
28
JP4708329B2
14
JP4738172B2
28

Sample Use Guides

In Vivo Use Guide
Adults: The recommended oral dose of AGENERASE Capsules for adults is 1200 mg (eight 150-mg capsules) twice daily in combination with other antiretroviral agents. Concomitant Therapy: If AGENERASE and ritonavir are used in combination, the recommended dosage regimens are: AGENERASE 1200 mg with ritonavir 200 mg once daily or AGENERASE 600 mg with ritonavir 100 mg twice daily. Pediatric Patients: For adolescents (13 to 16 years), the recommended oral dose of AGENERASE Capsules is 1200 mg (eight 150-mg capsules) twice daily in combination with other antiretroviral agents. For patients between 4 and 12 years of age or for patients 13 to 16 years of age with weight of <50 kg, the recommended oral dose of AGENERASE Capsules is 20 mg/kg twice daily or 15 mg/kg 3 times daily (to a maximum daily dose of 2400 mg) in combination with other antiretroviral agents.
Route of Administration: Oral
In Vitro Use Guide
The in vitro antiviral activity of amprenavir was evaluated against HIV-1 IIIB in both acutely and chronically infected lymphoblastic cell lines (MT-4, CEM-CCRF, 43 H9) and in peripheral blood lymphocytes. The 50% inhibitory concentration (IC50) of amprenavir ranged from 0.012 to 0.08 µM in acutely infected cells and was 0.41 µM in chronically infected cells (1 µM = 0.50 mcg/mL).
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:48:47 GMT 2023
Edited
by admin
on Fri Dec 15 15:48:47 GMT 2023
Record UNII
5S0W860XNR
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
AMPRENAVIR
EMA EPAR   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
AMPRENAVIR [EMA EPAR]
Common Name English
VX-478
Code English
AMPRENAVIR [VANDF]
Common Name English
AMPRENAVIR [MART.]
Common Name English
KVX-478
Code English
(3S-(3R*(1R*,2S*)))-(3-(((4-AMINOPHENYL)SULFONYL)(2-METHYLPROPYL)AMINO)-2-HYDROXY-1-(PHENYLMETHYL)PROPYL) TETRAHYDRO-3-FURANYL CARBAMATE
Common Name English
AMPRENAVIR [MI]
Common Name English
AMPRENAVIR [HSDB]
Common Name English
141W94
Code English
AMPRENAVIR [ORANGE BOOK]
Common Name English
J05AE05
Code English
AMPRENAVIR [USAN]
Common Name English
AGENERASE
Brand Name English
AMPRENAVIR [JAN]
Common Name English
Amprenavir [WHO-DD]
Common Name English
amprenavir [INN]
Common Name English
141W94
Code English
(3S)-Tetrahydro-3-furyl [(αS)-α-[(1R-1-hydroxy-2-(N1-isobutylsulfanilamido)ethyl]phenethyl]carbamate
Common Name English
Classification Tree Code System Code
EMA ASSESSMENT REPORTS AGENERASE (WITHDRAWN: HIV INFECTIONS)
Created by admin on Fri Dec 15 15:48:47 GMT 2023 , Edited by admin on Fri Dec 15 15:48:47 GMT 2023
WHO-ATC J05AE05
Created by admin on Fri Dec 15 15:48:47 GMT 2023 , Edited by admin on Fri Dec 15 15:48:47 GMT 2023
NDF-RT N0000175889
Created by admin on Fri Dec 15 15:48:47 GMT 2023 , Edited by admin on Fri Dec 15 15:48:47 GMT 2023
NCI_THESAURUS C97366
Created by admin on Fri Dec 15 15:48:47 GMT 2023 , Edited by admin on Fri Dec 15 15:48:47 GMT 2023
NDF-RT N0000000246
Created by admin on Fri Dec 15 15:48:47 GMT 2023 , Edited by admin on Fri Dec 15 15:48:47 GMT 2023
WHO-VATC QJ05AE05
Created by admin on Fri Dec 15 15:48:47 GMT 2023 , Edited by admin on Fri Dec 15 15:48:47 GMT 2023
LIVERTOX NBK548011
Created by admin on Fri Dec 15 15:48:47 GMT 2023 , Edited by admin on Fri Dec 15 15:48:47 GMT 2023
Code System Code Type Description
NDF-RT
N0000182141
Created by admin on Fri Dec 15 15:48:47 GMT 2023 , Edited by admin on Fri Dec 15 15:48:47 GMT 2023
PRIMARY Cytochrome P450 3A4 Inhibitors [MoA]
DAILYMED
5S0W860XNR
Created by admin on Fri Dec 15 15:48:47 GMT 2023 , Edited by admin on Fri Dec 15 15:48:47 GMT 2023
PRIMARY
NDF-RT
N0000185506
Created by admin on Fri Dec 15 15:48:47 GMT 2023 , Edited by admin on Fri Dec 15 15:48:47 GMT 2023
PRIMARY Cytochrome P450 3A4 Inducers [MoA]
DRUG CENTRAL
200
Created by admin on Fri Dec 15 15:48:47 GMT 2023 , Edited by admin on Fri Dec 15 15:48:47 GMT 2023
PRIMARY
MESH
C095108
Created by admin on Fri Dec 15 15:48:47 GMT 2023 , Edited by admin on Fri Dec 15 15:48:47 GMT 2023
PRIMARY
RXCUI
228656
Created by admin on Fri Dec 15 15:48:47 GMT 2023 , Edited by admin on Fri Dec 15 15:48:47 GMT 2023
PRIMARY RxNorm
PUBCHEM
65016
Created by admin on Fri Dec 15 15:48:47 GMT 2023 , Edited by admin on Fri Dec 15 15:48:47 GMT 2023
PRIMARY
NCI_THESAURUS
C28824
Created by admin on Fri Dec 15 15:48:47 GMT 2023 , Edited by admin on Fri Dec 15 15:48:47 GMT 2023
PRIMARY
INN
7751
Created by admin on Fri Dec 15 15:48:47 GMT 2023 , Edited by admin on Fri Dec 15 15:48:47 GMT 2023
PRIMARY
EPA CompTox
DTXSID5046061
Created by admin on Fri Dec 15 15:48:47 GMT 2023 , Edited by admin on Fri Dec 15 15:48:47 GMT 2023
PRIMARY
DRUG BANK
DB00701
Created by admin on Fri Dec 15 15:48:47 GMT 2023 , Edited by admin on Fri Dec 15 15:48:47 GMT 2023
PRIMARY
CHEBI
40050
Created by admin on Fri Dec 15 15:48:47 GMT 2023 , Edited by admin on Fri Dec 15 15:48:47 GMT 2023
PRIMARY
USAN
JJ-94
Created by admin on Fri Dec 15 15:48:47 GMT 2023 , Edited by admin on Fri Dec 15 15:48:47 GMT 2023
PRIMARY
ChEMBL
CHEMBL116
Created by admin on Fri Dec 15 15:48:47 GMT 2023 , Edited by admin on Fri Dec 15 15:48:47 GMT 2023
PRIMARY
WIKIPEDIA
AMPRENAVIR
Created by admin on Fri Dec 15 15:48:47 GMT 2023 , Edited by admin on Fri Dec 15 15:48:47 GMT 2023
PRIMARY
FDA UNII
5S0W860XNR
Created by admin on Fri Dec 15 15:48:47 GMT 2023 , Edited by admin on Fri Dec 15 15:48:47 GMT 2023
PRIMARY
MERCK INDEX
m1855
Created by admin on Fri Dec 15 15:48:47 GMT 2023 , Edited by admin on Fri Dec 15 15:48:47 GMT 2023
PRIMARY Merck Index
NDF-RT
N0000191264
Created by admin on Fri Dec 15 15:48:47 GMT 2023 , Edited by admin on Fri Dec 15 15:48:47 GMT 2023
PRIMARY P-Glycoprotein Inducers [MoA]
CAS
161814-49-9
Created by admin on Fri Dec 15 15:48:47 GMT 2023 , Edited by admin on Fri Dec 15 15:48:47 GMT 2023
PRIMARY
SMS_ID
100000089388
Created by admin on Fri Dec 15 15:48:47 GMT 2023 , Edited by admin on Fri Dec 15 15:48:47 GMT 2023
PRIMARY
EVMPD
SUB00511MIG
Created by admin on Fri Dec 15 15:48:47 GMT 2023 , Edited by admin on Fri Dec 15 15:48:47 GMT 2023
PRIMARY
HSDB
7157
Created by admin on Fri Dec 15 15:48:47 GMT 2023 , Edited by admin on Fri Dec 15 15:48:47 GMT 2023
PRIMARY
Related Record Type Details
OATP1B1
TRANSPORTER -> INHIBITOR
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
The high affinity binding protein for amprenavir is alpha1-acid glycoprotein (AAG).
BINDING
Structure of AMPRENAVIR MESYLATE
SALT/SOLVATE -> PARENT
HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 PROTEASE
TARGET -> INHIBITOR
MULTIDRUG RESISTANCE PROTEIN 1
TRANSPORTER -> SUBSTRATE
Structure of AMPRENAVIR
EXCRETED UNCHANGED
URINE
CYTOCHROME P450 3A4
METABOLIC ENZYME -> SUBSTRATE
MAJOR
CYTOCHROME P450 3A5
METABOLIC ENZYME -> SUBSTRATE
CYTOCHROME P450 3A4
METABOLIC ENZYME -> INHIBITOR
HUMAN IMMUNODEFICIENCY VIRUS TYPE 1
TARGET ORGANISM->INHIBITOR
OATP-8
TRANSPORTER -> INHIBITOR
ATP-BINDING CASSETTE SUB-FAMILY G MEMBER 2
TRANSPORTER -> INHIBITOR
Related Record Type Details
Structure of R-374699
METABOLITE -> PARENT
IN VITRO
Structure of CARBAMIC ACID, (3-(((4-AMINOPHENYL)SULFONYL)(2-METHYLPROPYL)AMINO)-2-HYDROXY-1-(PHENYLMETHYL)PROPYL)-, 3-HYDROXY-1-(HYDROXYMETHYL)PROPYL ESTER, (1S-(1R*(R*),2S*))-
METABOLITE -> PARENT
Structure of FOSAMPRENAVIR
PRODRUG -> METABOLITE ACTIVE
Related Record Type Details
Structure of AMPRENAVIR
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Tmax PHARMACOKINETIC SINGLE DOSE

ORAL ADMINISTRATION

Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966